anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a medicine for diabetes of type II independent of insulin containing specific sesquiterpene analogs and a salt thereof as active ingredient. CONSTITUTION:The objective medicine for diabetes contains compounds expressed by formulas I and II and a basic compound salt thereof as active ingredient. The compound expressed by formula I is dissolved in a basic solvent to form an equilibrium mixture with the compound expressed by formula II as a tautomer and resultant mixture is directly able to be used as active ingredient. As the basic compound forming salt, hydroxide or carbonate of alkali (earth) metal or organic amount (e.g. ethylamine or piperazine), etc., are exemplified. Formulation carrier such as filler, binder, wetting agent, disintegrator, surfactant or lubricant is used together with the active ingredient to form a formulation of tablet, pellet, powder, solution, capsule, granule, suppository or injecting agent, etc. Administration dose is 0.1-50mg (as amount of active ingredient) to an adult per 1 day.
Colchicine is significantly excreted in urine in healthy subjects. Clearance of colchicine is decreased in patients with impaired renal function. Total body clearance of colchicine was reduced by 75% in patients with end-stage renal disease undergoing dialysis.

Prophylaxis of Gout Flares 

For prophylaxis of gout flares in patients with mild (estimated creatinine clearance Clcr 50 to 80 mL/min) to moderate (Clcr 30 to 50 mL/min) renal function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of colchicine. However, in patients with severe impairment, the starting dose should be 0.3 mg per day and any increase in dose should be done with close monitoring. For the prophylaxis of gout flares in patients undergoing dialysis, the starting doses should be 0.3 mg given twice a week with close monitoring [see Dosage and Administration (2.5)].

Treatment of Gout Flares 

For treatment of gout flares in patients with mild (Clcr 50 to 80 mL/min) to moderate (Clcr 30 to 50 mL/min) renal function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of colchicine. However, in patients with severe impairment, while the dose does not need to be adjusted for the treatment of gout flares, a treatment course should be repeated no more than once every two weeks. For patients with gout flares requiring repeated courses, consideration should be given to alternate therapy. For patients undergoing dialysis, the total recommended dose for the treatment of gout flares should be reduced to a single dose of 0.6 mg (one tablet). For these patients, the treatment course should not be repeated more than once every two weeks [see Dosage and Administration (2.5)].

FMF 

Although, pharmacokinetics of colchicine in patients with mild (Clcr 50 to 80 mL/min) and moderate (Clcr 30 to 50 mL/min) renal impairment is not known, these patients should be monitored closely for adverse effects of colchicine. Dose reduction may be necessary. In patients with severe renal failure (Clcr less than 30 mL/min) and end-stage renal disease requiring dialysis, Colchicine tablets may be started at the dose of 0.3 mg/day. Any increase in dose should be done with adequate monitoring of the patient for adverse effects of colchicine. [see Clinical Pharmacology (12.3), Dosage and Administration (2.5)].
The invention relates to the technical field of biology, in particular to a double-layer hydrogel microsphere and application thereof. The invention designs a double-layer hydrogel microsphere capable of responding to an OA microenvironment. Firstly, celecoxib (CLX) is encapsulated into liposome by a film dispersion method; secondly, preparing the inner layer microsphere of the methacryloyl chondroitin sulfate (ChsMA) by utilizing a microfluidic technology. Finally, the freeze-dried ChsMA microsphere is soaked in CLX@Lipo@GelMA, so that a layer of CLX@Lipo@GelMA shell is formed on the surface of the ChsMA microsphere. The outer GelMA layer can respond to rapid degradation of MMPs in the OA microenvironment to release the CLX-loaded liposome. The microsphere is lubricated, the released CLX plays an anti-inflammatory role, and after the outer layer is degraded, the core structure of the ChsMA microsphere is exposed and starts to degrade, so that the repair of damaged cartilage of the OA joint is promoted, and the OA is treated.
The invention discloses a solanum lyratum extract, and an anticancer medicine comprising the solanum lyratum extract. The solanum lyratum extract is prepared through steps that: a solanum lyratum medicinal material is extracted by using ethanol, wherein the solanum lyratum medicinal material is processed through ethanol refluxing extraction, the recovered solvent is evaporated until dried, such that an ethanol extract is obtained; the extract is refined, wherein the ethanol extract is dissolved in water to form a solution, the solution is absorbed by using a weak acidic cation exchange macroporous resin column and is orderly eluted by using ethanol and hydrochloric ethanol, the hydrochloric ethanol eluent is collected and is neutralized by using ammonia water, and the collected product is desalted, such that the solanum lyratum extract is prepared. The solanum lyratum extract contains 1% to 60% of steroid alkaloid. According to the invention, weak acidic cation exchange macroporous resin is adopted, steroid alkaloid is specifically accumulated from various components of solanum lyratum. The component of accumulated steroid alkaloid is simple. As a result of experiments, the substance has a substantial anticancer potency, and the anticancer potency is greatly higher than that of solanum lyratum aqueous crude extracts and steroid saponins extracted by using n-butyl alcohol in prior arts.
Screening of asymptomatic women for Breast and Cervical cancer in the age group of 35-64 years. Diagnostic assessment of symptomatic women for Ovarian and Endometrial cancer in the age group of 50-64 years.
Vitamin D plays a role in inflammatory skin disease, but the exact mechanisms and the clinical significance remain unclear. According to the free hormone hypothesis, it is the free concentration of 25-hydroxy vitamin D (25(OH)D) that is biologically active. Vitamin D-binding protein (DBP) acts as the major transporter of vitamin D in the circulation, and DBP concentration defines the free 25(OH)D levels. DBP levels are elevated in various inflammatory conditions, including psoriasis. Narrowband-ultraviolet B (NB-UVB) is the most widely used phototherapy and is an established first-line treatment for psoriasis and atopic dermatitis (AD), often used before proceeding to systemic treatment. The aim of this study was to investigate the influence of NB-UVB phototherapy on DBP and high-sensitivity C-reactive protein (hsCRP) levels, as markers of systemic inflammation, in inflammatory skin disease. Thirty adults (psoriasis (n = 20) and AD (n = 10)) were treated with NB-UVB. Serum DBP, hsCRP, total and free 25(OH)D, and 1,25-dihydroxy vitamin D (1,25(OH)2D) were measured before and after NB-UVB. Disease severity was assessed with Psoriasis Area and Severity Index (PASI), SCORing Atopic Dermatitis (SCORAD), and Visual Analogue Scale (VAS). DBP decreased in psoriasis patients and varied with no clear trend in AD patients. HsCRP decreased in both groups, but this did not reach statistical significance. PASI, SCORAD, and VAS improved, and vitamin D levels increased after NB-UVB. Sub-analysis indicated a better response to NB-UVB for patients with vitamin D deficiency and insufficiency compared to vitamin D-sufficient patients. The decrease in DBP after NB-UVB in psoriasis patients suggests a potential systemic anti-inflammatory effect of phototherapy. Measurement of vitamin D levels may potentially serve as a tool to identify patients who would derive the greatest benefit from NB-UVB phototherapy.
Pharmacokinetic studies with intravenous azithromycin have not been performed in older volunteers. Pharmacokinetics of azithromycin following oral administration in older volunteers (65 to 85 years old) were similar to those in younger volunteers (18 to 40 years old) for the 5-day therapeutic regimen.

In multiple-dose clinical trials of intravenous azithromycin in the treatment of community-acquired pneumonia, 45% of patients (188/414) were at least 65 years of age and 22% of patients (91/414) were at least 75 years of age. No overall differences in safety were observed between these subjects and younger subjects in terms of adverse reactions, laboratory abnormalities, and discontinuations. Similar decreases in clinical response were noted in azithromycin- and comparator-treated patients with increasing age.

Azithromycin for injection contains 114 mg (4.96 mEq) of sodium per vial. At the usual recommended doses, patients would receive 114 mg (4.96 mEq) of sodium. The geriatric population may respond with a blunted natriuresis to salt loading. The total sodium content from dietary and non-dietary sources may be clinically important with regard to such diseases as congestive heart failure.

Elderly patients may be more susceptible to development of torsades de pointes arrhythmias than younger patients [see Warnings and Precautions (5.4)].
Participants will complete the baseline assessments and continue with standard of care (no intervention) for 12-weeks then return for a repeat assessment. Participants will then crossover into the MedBIKE HIIT Exercise Program intervention group for 12-weeks. A post-intervention assessment will be completed and follow-up assessments at 6- and 12-months post intervention.
Stroke and subsequent neuroregenerative processes cause changes in neural organization of attentional functions. In this study, we attempted to identify differences in neural synchronization patterns during a visual Go/No-Go task in people with post-stroke aphasia in both subacute and chronic stroke phases. To identify neuronal underpinnings of the behavioral differences we investigated pairwise connectivity patterns using corrected imaginary phase locking value and graph-theoretic measures (efficiency, modularity and clustering coefficient) at global and local level in subacute (n = 13) and chronic stroke phases (n = 14) during a Go/No-Go task. We observed significantly lower phase synchronization in the Subacute Group in the alpha band in the connections spanning frontal and central areas of both hemispheres alongside lower local efficiency and clustering coefficient in the left frontal region. Additionally, we observed higher modularity in the beta band in the unaffected right parietal region in the Subacute Group which may denote inhibition of motor and attention functions. Those mechanisms could serve to align cognitive abilities between the damaged and healthy hemispheres, harmonizing the activity of the neuronal networks of both hemispheres disrupted by the effects of the stroke. Our findings have potential implications for rehabilitation therapies, which should take into account the pattern of connectivity changes during different phases of reovery.
Participants in this group will receive probiotic Streptococcus salivarius eK12 (Bactoblis® EVOLcontaining ca. 1 billion CFU of Streptococcus salivarius eK12/capsule) as daily one capsule (to be slowly dissolved in the mouth before sleeping at night time) for 3-months. There will be a further 3-months follow-up period.
PURPOSE:To obtain granules useful as a base material for cosmetic, having excellent light resistance, alkali resistance, acid resistance and good adaptability to the skin free from collapse of shape, by making chitosan granules crosslinked with a bifunctional reagent include a colorant. CONSTITUTION:Chitosan granules are crosslinked with a bifunctional reagent [e.g. hexamethylenediisocyanate, alkylbis-(2,3-epoxypropyldialkylammonium halide) or glutaraldehyde] usually in water or a polar solvent to give granules, which are sufficiently blended with a colorant in water. The prepared dispersed suspension is spray-dried in a high-temperature atmosphere to give the aimed granules. Cobalt titanate, ultramarine blue, Red 201 or chlorophyll is preferable as the colorant. When the granules are used as a base material for cosmetic, chitosan having 1-100mum particle diameter is used and preferably 0.01-1pt.wt. very fine powder of titanium oxide having 0.01-0.05mum particle diameter is added to 1pt.wt. chitosan granules.
Oral pomalidomide 1 mg - 5 mg daily (QD) for 14 consecutive days of a 21-day cycle, in combination with intravenous (IV) cisplatin 25 mg/m\^2 and IV etoposide 100 mg/m\^2 on Days 1, 2 and 3 of each cycle during the dose-finding phase (Treatment and Extension Periods; 6 cycles in total). Dose escalation followed a standard phase 1 3+3 design. Participants continuing took only their pomalidomide dose (monotherapy) for an additional 3-week Recovery Period (14 days of consecutive dosing followed by 7 days of no study medication). Participants continuing took oral pomalidomide 5 mg QD as monotherapy for 14 consecutive days of each 21-day cycle until disease progression in the Maintenance Phase.
PURPOSE: A biopin containing two or more cell penetrating peptide conjugated to membrane proteins is provided to enhance physical bond and to be used in a nano bio field. CONSTITUTION: A fusion protein contains a membrane protein and two or more cell penetrating peptide(CPP) conjugated to the protein. The membrane protein contains an opioid receptor delta transmembrane domain 1(OPRD TM1). The cell penetrating peptide is trans-activating transcriptional activator(Tat), Antp, Mph-1, VP22, or HP4. A method for preparing the fusion protein comprises a step of isolating and purifying fusion proteins from a transformant culture. A contrast composition contains the fusion protein and pharmaceutically acceptable carriers. [Reference numerals] (AA) Partial domain of certain membrane protein of cell
Mutations in BRCA1 and BRCA2 significantly elevate the risk of developing breast and ovarian cancer. Limited data exists regarding the prevalence of BRCA mutations, and optimal, cost-effective testing strategies in developing countries like India. This study aimed to evaluate the utility of a Next Generation Sequencing (NGS) panel for BRCA1/2 mutation testing among women diagnosed with, or at risk of developing hereditary breast and ovarian cancers. We also aimed to identify population specific BRCA1/2 mutation hotspots, to enable the development of more affordable testing strategies. We identified 921 patients with breast and ovarian cancer who underwent mutation testing. The target enrichment was followed by targeted NGS in 772 patients and an allele-specific PCR (ASPCR) based genotyping for BRCA1:c.68_69delAG (or 185delAG), was carried out in 149 patients. We identified 188 (20.4%) patients with BRCA1/2 variants: 118 (62.8%) with pathogenic/likely pathogenic and 70 (37.2%) with VUS. The 185delAG was identified as a recurrent mutation in the Southern Indian population, accounting for 24.6% of the pathogenic variants. In addition, a family history of breast, ovary, pancreas, or prostate (BOPP) cancer was found to be associated with an increased risk of identifying a deleterious BRCA1/2 variant [OR = 2.11 (95% CI 1.45-3.07) p ≤ 0.001]. These results suggest that Targeted NGS is a sensitive and specific strategy for BRCA testing. For Southern Indian patients, a two-tiered approach can be considered: Initial screening with ASPCR for BRCA1 185delAG followed by NGS for those testing negative. Expanding the gene panel and identifying other population-specific mutation hot spots is a promising area with potential for improvements in testing and treatment strategies.
Streptococcus pneumoniae is a major cause of pneumoniae, meningitis, and major cause of morbidity and mortality throughout the world by bacterial otitis media, pneumoniae, meningitis, and bacteraemia. It is an important agent of disease in man especially among infants, the elderly and immunocompromised persons. The present in vention provides a solution to this problem by providing a substantially pure or isolated disease related antigen selected from the group consisting of the isolated, recombinant or synthetic S. pneumoniae human immunogenic antigens of SP_0562, SP_0965, SP_0082 (in particular the fragments SP4 and SP 17 of said SP_0082), and a Periplasmic Binding Protein (PBP) (in particular SP_1683 or SP_1386), or a fragments thereof or substantially identical antigen for use in a treatment to induce a immunological memory in a human against S. pneumoniae cells for use in a vaccination treatment of S. pneumoniae disorder in human or against S. pneumoniae in a human. In a particular embodiment, the present invention provides an isolated, recombinant or synthetic S. pneumoniae Periplasmic Binding Protein (PBP) (in particular SP_1683 or SP_1386) as a disease related antigen for use in a treatment to induce a immunological memory in a human against S. pneumoniae cells for use in a vaccination treatment of S. pneumoniae disorder in human or for use in the treatment of an S. pneumoniae infection in a human. It further provides antibodies that specifically bind to the S. pneumoniae disease related antigens identified herein for use in the treatment of a an S. pneumoniae infection in a human, such as for example in a treatment to induce a immunological memory in a human against S. pneumoniae, i.e. in a vaccination treatment of S. pneumoniae. It is also an aspect of the present invention to provide the use of any one of the S. pneumoniae disease related antigens as identified herein, or of the antibodies specific for said antigens in methods to diagnose for a S. pneumoniae disorder in a human.
BACKGROUND AND OBJECTIVE: Spinal cord infarction (SCI) is a rare type of stroke, with no proposed classification or diagnostic criterium widely accepted and used in daily clinical practice currently. We try to explore the clinical manifestations and MRI features of SCI for improving the accurate diagnosis of SCI.
METHODS: Retrospectively analyzed the clinical data, MRI features, laboratory findings and outcomes of 40 patients who had been consecutively diagnosed with SCI in our hospital from June 2016 to January 2022.
RESULTS: Most of the SCI (92.5%) occurred at the level of T8-L2 and C4-T4. Transverse infarction (52.5%) and ASA territory infarction (27.5%) were the most common patterns. Longitudinally extensive lesions were noticed in 67.5% of the SCI and it might be a risk factor of poor prognosis (OR=21.11, 95%CI 2.14-208.29). Restricted diffusion of the SCI lesion occurred in 8h and a few lasted up to 60 days. All SCI showed spinal cord edema, accompanied by enhancement of the ventral cauda equina (13.8%), weakened enhancement of the dorsal venous plexus (44.8%), and vertebral infarction (25%). Most patients developed a stroke-like onset (92.5%) after movement (57.5%), with definite pain in the trunk or limbs (67.5%) and dissociative sensory disturbance (60.0%). The main etiologies of them include vascular abnormalities (45%) and iatrogenic injuries (15%).
CONCLUSION: An MRI classification of SCI based on the spinal cord blood supply was proposed. Restricted diffusion and co-existing abnormality of vertebral body and cauda equina may be the key neuroimaging feature for SCI diagnosis. Detailed history of vascular diseases or triggering factors are also helpful.
PURPOSE:To enable a variety of vehicle informations to be read in a short time and conducting a labor saving and a speed-up for a vehicle check operation by mounting the whole components of a transponder in one sheetwise package and sticking the package to the window glass or the like of a vehicle. CONSTITUTION:A sticker for a vehicle is constituted such that the whole components of a transponder are mounted in a square sheetwise plastic package and a paste is applied to one surface of the package, enabling it to be sticked to the glass surface of the vehicle. When radio waves with a predetermined frequency act on a coil 2, high frequency signals are inputted to a power supply circuit 5 and a timing control circuit 6 via a tuning circuit 4. The circuit 5 rectifies and smoothes the signals to develop a DC voltage, which is outputted therefrom as the power supply of circuits. The circuit 6, when receives the signals for a given time or more, gives a starting signal and clock signals to a modulating circuit 9. The circuit 9, in synchronism with those signals, sequentially reads vehicle information codes stored in a memory 7 one bit by one bit and, after modulating and amplifying (10) the output of an oscillation circuit 8, emits the output to outside from the coil 2 as radio waves.
HIV is spreading more rapidly in Eastern Europe than anywhere else in the world. Bulgaria and Hungary are still in the early stages of the crisis. However, without efforts to prevent the spread of HIV and AIDS, both countries are likely to fall victim to the HIV/AIDS growth curve that has already affected the rest of Eastern Europe. Bulgarian and Hungarian young men who have sex with men (YMSM) and Roma men and women are at the greatest risk for HIV infection. In both countries, HIV is spread primarily through sexual transmission. Prevention efforts that are undertaken now could help these countries avoid an explosive HIV/AIDS epidemic. YMSM and Roma men in Bulgaria and Hungary are more likely to trust HIV/AIDS information received from someone they know than from an official statement. Therefore, entire social networks will be recruited for this study and the leader of each network will be responsible for delivering the prevention information to his or her peers. This study will evaluate the effectiveness of peer-led HIV/STD risk reduction educational counseling in reducing HIV risk behavior among the social networks of YMSM and Roma men and women in Bulgaria and Hungary.

This study will recruit 40 YMSM and 40 Roma high-risk social networks. Each network will be randomly assigned to receive either standard HIV/AIDS risk reduction or the intervention. Networks assigned to receive the intervention will be assessed sociometrically to determine the 'social influence' leaders of each group. The leaders will then attend a 9-session program over the course of 3 months that will train them to deliver theory-based risk-reduction messages and peer-counseling to their respective social networks. The messages will focus on promoting safer sex knowledge, attitudes, intentions, perceived norms, and self-efficacy. All participants will be offered STD testing and their HIV-risk behavior will be assessed at Months 3 and 12. Participants assigned to receive the standard HIV/AIDS risk reduction will then receive the network intervention for an additional 12 months.
The present disclosure belongs to the field of protein construction, in particular to an ultramarine fluorescent protein and its construction method and use thereof in preparation of protein sunscreen agent, and further relates to a sunscreen agent containing the ultramarine fluorescent protein. An ultramarine fluorescent protein, is a protein selected from (a) and (b) protein: (a) a protein consisting of an amino acid sequence set forth in SEQ IDzNO. 2; (b) a protein derived from (a) by substitution, deletion or addition with one or more amino acids in the amino acid sequence of (a) and having activity of the ultramarine fluorescent protein. The ultramarine fluorescent protein (UFP) has the characteristics of pH-insensitivity and light stability, and its chromophore can absorb long-wavelength ultraviolet (UVA) and release fluorescence at wavelength longer than 400 nm. And the aromatic amino acids residue (with content of 9.2%) can absorb medium wavelength ultraviolet (UVB) and release UVA. UVA can be further absorbed by chromophore by resonance energy transfer. UFP is possibility to be developed as a protein sunscreen.